Drug discovery company STORM Therapeutics reported on Friday that it has raised another GBP14m to bring the total Series A financing to GBP30m.

The new financing includes the new investor, Seroba Life Sciences as well as existing investors, Cambridge Innovation Capital, M Ventures, Pfizer Ventures, Taiho Ventures and IP Group.

According to STORM, it will use the funds to advance its broad pipeline in preclinical development, accelerate its programmes towards the clinic as well as support its growth as the leading RNA modulating enzymes drug discovery company.

In addition, STORM has named Dr Mark Albertella as VP Translational Oncology. Mark was previously Director of Biology at Medivir AB as well as part of Argenta, OSI Pharmaceuticals, Kudos and AstraZeneca.

On 21 May, STORM Therapeutics' CEO Keith Blundy will give a presenatation at the BioEquity Europe 2019 meeting in Barcelona at 9:00 CEST.

(USD1=GBP0.784529)